Sequent Scientific Limited has informed the Exchange regarding Board meeting held on August 08, 2025.

Pat Growth 25pctRevenue DeclineExceptional ItemEbitda Margin ExpansionResults View source PDF Explain this filing

VIYASH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.6%Reaction day

₹174.80

prior close

₹173.13

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.8%-2.8% vs market

Pharmaceuticals peers, median of 147sector-0.8%-2.8% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.7

10m

+0.3

15m

+1.6

30m

+1.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.6-0.8-2.8-0.8-2.8

Next day

+0.7-0.7+1.4-0.6+1.3

-0.4-0.6+0.3-0.3-0.1

-1.9+0.0-1.9-0.5-1.5

+0.0-0.8+0.8-0.6+0.6

+0.0+0.7-0.7-0.9+0.9

+1.2+1.9-0.7-0.1+1.3

15d

-1.6+0.9-2.5-0.8-0.8

+5.9+1.7+4.2-1.0+6.9

+23.0+0.2+22.8-1.3+24.3

+28.7+0.8+27.9-4.7+33.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SeQuent Scientific's Board, meeting on August 8, 2025, approved its Q1 FY26 (quarter ended June 30, 2025) unaudited results. Consolidated revenue from operations rose to Rs. 4,414.20 million from Rs. 3,902.10 million a year earlier, with profit after tax nearly doubling to Rs. 175.70 million (vs Rs. 90.50 million) and basic EPS of Rs. 0.57 (vs Rs. 0.26). Standalone performance was weaker, with revenue dropping to Rs. 410.70 million from Rs. 576.70 million and standalone PAT falling to Rs. 33.70 million. The Group booked Rs. 12.50 million in exceptional costs related to the ongoing Composite Scheme of Amalgamation involving Viyash Life Sciences, Symed Labs, and other entities, which is still awaiting approvals. SRBC & Co LLP issued an unmodified limited review report on both standalone and consolidated results.

Likely market impact

Strong consolidated earnings growth and improving profitability are positive signals, but a sharp standalone revenue decline and pending large amalgamation scheme create mixed sentiment for shareholders. Near-term stock reaction may hinge on progress of the merger approvals and standalone business recovery.